BLOCKADE OF RIPK3 ATTENUATES FOLIC ACIDINDUCED KIDENY FIBROSIS OF C57BL/6 MOUSE

Y SHI1, Y ZHAO2, CL HUANG1, X CHEN1, C POLLOCK1

1Kolling Institute, University of Sydney, Royal North Shore Hospital, Sydney, New South Wales; 2The Second Hospital, Dalian Medical University, China

Aim: To define the role of RIPK3 blocking in alleviating renal fibrogenesis.

Background: Current therapies for renal fibrosis are largely ineffective. Therefore, identification of novel therapeutic targets is essential. RIPK3 is identified as a crucial regulator of necrosis, apoptosis and inflammation, which have been well recognized to be involved in renal fibrogenesis. To date, the role of RIPK3 in renal fibrosis has not been reported.

Methods: C57BL/6 wild-type and RIPK3 gene knock out (RIPK3-/-) mice and two interventional strategies were used in the study. 1. Folic acid was administrated i.p. to induce kidney injury in both WT and RIPK3-/- mice for 28 days; 2. C57BL/6 WT mice injected with folic acid were treated with Dabrafenib (RIPK3 inhibitor) or vehicle respectively for 28 days. Kidneys were harvested from above experiments and kidney function was assessed by measuring 24 hour of urinary albumin excretion and urinary albumin creatinine ratio (UACR) by ELISAs. Kidney histological change and collagen deposition was assessed by PAS, Masson’s trichrome and picrosirius red staining. MCP-1, TGF-β and a-SMA RNA expression level were detected by quantitative RTPCR analysis.

Results: RIPK3 blockade reversed folic acid increased 24 hour urinary albumin excretion and decreased UACR compared to WT or vehicle control groups treated with folic acid. Histological analysis has shown that folic acid
resulted in increased collagen accumulation and ECM deposition, whereas, RIPK3 inhibition attenuated ECM deposition and renal fibrosis. In addition, quantitative RT-PCR demonstrated Dabrafenib treated mice and RIPK3-/-
mice inhibited RNA expression of MCP-1 TGF-β and a-SMA. Conclusions: These results suggest that RIPK3 blockade may be a potential novel target in renal fibrosis.

About ANZSN

The ASM is hosted by Australian and New Zealand Society of Nephrology.

The aims of the Society are to promote and support the study of the kidney and urinary tract in health and disease, and to ensure the highest professional standards for the practice of nephrology in Australia and New Zealand.

Conference Managers

Please contact the team at Conference Design with any questions regarding the Annual Scientific Meeting

/wp-content/uploads/2017/08/Conference-Design-400×400.png

© 2015 - 2016 Conference Design Pty Ltd